Show simple item record

Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.

dc.contributor.authorGriffiths, Richard W
dc.contributor.authorZee, Ying-Kiat
dc.contributor.authorEvans, Saran
dc.contributor.authorMitchell, Claire L
dc.contributor.authorKumaran, Gireesh C
dc.contributor.authorWelch, Richard
dc.contributor.authorJayson, Gordon C
dc.contributor.authorClamp, Andrew R
dc.contributor.authorHasan, Jurjees
dc.date.accessioned2011-01-24T13:24:37Z
dc.date.available2011-01-24T13:24:37Z
dc.date.issued2011-01
dc.identifier.citationOutcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube. 2011, 21 (1):58-65 Int. J Gynecol Canceren
dc.identifier.issn1525-1438
dc.identifier.pmid21178570
dc.identifier.doi10.1097/IGC.0b013e3182049273
dc.identifier.urihttp://hdl.handle.net/10541/120281
dc.description.abstract: Platinum-resistant and refractory cancers of the ovary, fallopian tube, and peritoneum have a poor prognosis, yet in some cases, they can respond to multiple lines of chemotherapy. Uncertainty remains over optimal drug choice and when therapeutic focus should be switched from active therapy to supportive care.
dc.language.isoenen
dc.subjectOvarian Canceren
dc.subjectChemotherapyen
dc.subjectFallopian Tube Canceren
dc.subjectTreatment Resistanceen
dc.titleOutcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.en
dc.typeArticleen
dc.contributor.departmentDepartments of *Medical Oncology, and †Clinical Oncology, The Christie NHS Foundation Trust; and ‡School of Cancer and Enabling Science, University of Manchester, Manchester, UK.en
dc.identifier.journalInternational Journal of Gynecological Canceren
html.description.abstract: Platinum-resistant and refractory cancers of the ovary, fallopian tube, and peritoneum have a poor prognosis, yet in some cases, they can respond to multiple lines of chemotherapy. Uncertainty remains over optimal drug choice and when therapeutic focus should be switched from active therapy to supportive care.


This item appears in the following Collection(s)

Show simple item record